ENDRA Life Sciences Inc. (NDRA) Stock Score, Valuation & Financial Research

ENDRA Life Sciences Inc. is in the Healthcare sector and Medical - Diagnostics & Research industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for NDRA

ENDRA Life Sciences Inc. does not currently have a complete Wall Street Score. The stored market price is USD 6.03. These figures are a research snapshot, not a buy or sell recommendation.

What ENDRA Life Sciences Inc. does

ENDRA Life Sciences Inc. specializes in advancing the capabilities of clinical diagnostic ultrasound. The company's primary development is thermo-acoustic enhanced ultrasound technology, which operates by emitting sound waves that echo off internal body components such as tissues, organs, and blood. This innovation is utilized in managing nonalcoholic fatty liver disease, meticulously monitoring temperature during thermoablative surgical procedures, detailed vascular imaging, and assessing tissue perfusion. Furthermore, ENDRA offers other diagnostic imaging modalities, including computed tomography (CT), magnetic resonance imaging (MRI), and conventional ultrasound. These instruments empower physicians to visualize internal anatomy, aiding in treatment guidance and the identification of various medical conditions like bone fractures, cancerous growths, indicators of heart disease, or internal bleeding. The company also maintains a research collaboration agreement with General Electric Company. Established in 2007, ENDRA Life Sciences Inc. is headquartered in Ann Arbor, Michigan.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

ENDRA Life Sciences is a development-stage company that intends to implement a subscription-based business model with monthly recurring revenue for its TAEUS technology, while also retaining a traditional direct product sale model. The company is currently focused on research and development and has not yet generated commercial revenue from its medical device products.

Products and services

  • The company is developing the TAEUS (Thermo-Acoustic Enhanced UltraSound) platform, a next-generation technology designed to measure liver fat for metabolic disease management and to assist in clinical diagnostic ultrasound applications.

Brands and product families

  • TAEUS — The core platform technology for thermo-acoustic enhanced ultrasound. Source

Customer types

Hospitals; Imaging Centers.

Suppliers, materials and equipment

  • Contract Manufacturers — The company utilizes third-party contract manufacturers for the production of its medical device components. Source

Business strengths to evaluate

  • Proprietary TAEUS technology platform Source

Business risks and research considerations

  • History of operating losses and lack of revenue Source
  • Dependence on regulatory approvals for commercialization Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

NDRA financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 6.03
Market capitalization:
7.66M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -5.92M
Free cash flow:
USD -5.2M
Cash:
USD 1.74M
Total debt:
USD 429.27K
EPS:
USD -6.33

What stands out

  • Free cash flow is USD -5.2M, negative for the stored period.
  • The balance sheet shows USD 1.74M of cash versus USD 429.27K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 1.31M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for NDRA

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can NDRA fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is NDRA likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for NDRA to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of NDRA's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-08.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research NDRA

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.